Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Saturday, January 31, 2009

Some extracts on FMO enzymes in books via googlebooks

The Flavin Mono-oxygenase 3 enzyme is said to be flawed in a diagnosis of Primary Trimethylaminuria (despite anecdotal test results of DNA suggesting otherwise, and also a dissertation where 8/12 had no mutants/variants). The enzyme deals with a lot of odorous substrates; sulfides and amines and phosphorus compounds. As textbooks currently say, since these other compounds are thought to be able to go a slower complex alternative route, via the P450 enzymes, (P450 and FMO are regarded as a layer of oxidizing activating/detoxing enzymes - the phase 1 enzymes) the other sulfides and amines aren't regarded as un-oxidizable as trimethylamine is. Perhaps this enzyme will turn out to be the main 'smelly' enzyme and perhaps the problem is to do with a backlog of these substrates. Trimethylamine doesn't seem to explain fecal body odor, whereas other sulfides and amines seem plausible.

For this reason, it is probabably useful to know about these enzymes, and in particular, FMO3. This is a good extract from a 2003 Molecular Toxicology book about the FMO family of enzymes.

Molecular Toxicology By Nick Plant: FMO

This chapter is from a 'gold standard' 2001 medical book on toxicology, the chapter dealing with the xenobiotic metabolizing enzymes (aka drug metabolizing enzymes, first pass enzymes, phase1/phase2 enzymes).

Casarett and Doull's Toxicology: Biotransformation of xenobiotics

0 comments:

Post a Comment